MAUPIN JOHN E JR D D S
Known title: DirectorCIK: 0001189149
Associated companies
Transaction History
| EHC | ▲ Buy | Grant | 8 | $578 | 4/19/2022 | View on chart |
| EHC | ▲ Buy | Grant | 298 | $0 | 4/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 7 | $429 | 1/19/2022 | View on chart |
| EHC | ▲ Buy | Grant | 343 | $0 | 1/18/2022 | View on chart |
| EHC | ▲ Buy | Grant | 9 | $598 | 10/18/2021 | View on chart |
| EHC | ▲ Buy | Grant | 311 | $0 | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date
Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.